RxDoctor Payments Data

Timothy Bateman, MD

Nuclear Cardiology · Kansas City, MONPI 1023076072

Payments from drug & device makers

$418,518in general payments, 2019–2025

Across 99 payments — averaging $4227.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$367K
  • Bracco Diagnostics Inc.$42K
  • Astrazeneca UK Limited$9K
  • Pfizer$297
  • Jubilant Draximage Inc.$74
  • AstraZeneca$41
$251,095in research payments, 2019–2025

Across 4 payments — averaging $62,774 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bracco Diagnostics Inc.$251K

What the payments were for

  • Consulting fees$66,85294%
  • Speaking & faculty fees$3,5255%
  • Travel & lodging$2820%
  • Food & beverage$7811%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GE HealthCare91$367,369
Bracco Diagnostics Inc.1$41,849
Astrazeneca UK Limited1$8,888
Pfizer4$297
Jubilant Draximage Inc.1$74
AstraZeneca1$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear cardiology providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$113,794
Medicare patients
1,067
Services billed
3,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$106,480
XareltoRivaroxaban21$18,290
Ezetimibe37$1,378
Atorvastatin Calcium122$1,322
Rosuvastatin Calcium78$1,203
Flecainide Acetate15$1,140
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$839
Metoprolol Succinate57$690
Carvedilol45$604
Amlodipine Besylate60$467
ClopidogrelClopidogrel Bisulfate22$439
Lisinopril31$368
Warfarin Sodium13$238
Losartan Potassium23$229
Isosorbide Mononitrate ErIsosorbide Mononitrate11$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$297$106,48095 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Missourion file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Kansas City

Where these figures come from

Is this you, or does something look wrong? →